Cardamonin
(Synonyms: 小豆蔻明; (E)-Cardamomin; (E)-Alpinetin chalcone) 目录号 : GC18069
A chalconoid with anti-inflammatory and anti-tumor activity
Cas No.:19309-14-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
IC50: 1.2 μM (NF-κB activation) [1]
Cardamonin (2′,4′-dihydroxy-6′-methoxychalcone), a chalcone isolated from the fruits of Alpinia rafflesiana, shows anti-inflammatory activity by targeting the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathway. NF-κB is a protein complex that controls cytokine production, transcription of DNA and cell survival.
In vitro: Cardamonin is a potential anti-inflammatory drug that targets the NF-κB pathway, which leads to suppress both NO and PGE2 synthesis, iNOS and COX-2 expression and enzymatic activity. The inhibition activation was due to a dose-dependent inhibition of phosphorylation and degradation of I-κBα, which resulted in a reduction of p65 NF-κB nuclear translocation [2]. Cardamonin also appears to inhibit prostaglandin E2, thromboxane B2 production, tumor necrosis factor a (TNF-a) release, and intracellular reactive oxygen species generation, all in a dose-dependent manner [3]
In vivo: Cardamonin shows protective effects on acute lung injury in sepsis. In mice, the results showed that cardamonin decreases systemic inflammatory responses, during sepsis, by downregulating TNF-a and interleukins [3].
Clinical trial: So far, no clinical study has been conducted.
References:
[1] Lee JH, Jung HS, Giang PM, Jin X, Lee S, Son PT, Lee D, Hong YS, Lee K, Lee JJ. Blockade of nuclear factor-kappaB signaling pathway and anti-inflammatory activity of cardamomin, a chalcone analog from Alpinia conchigera. J Pharmacol Exp Ther. 2006 Jan;316(1):271-8. Epub 2005 Sep 23.
[2] Israf DA, Khaizurin TA, Syahida A, Lajis NH, Khozirah S. Cardamonin inhibits COX and iNOS expression via inhibition of p65NF-kappaB nuclear translocation and Ikappa-B phosphorylation in RAW 264.7 macrophage cells. Mol Immunol. 2007 Feb;44(5):673-9. Epub 2006 Jun 13.
[3] Gonalves LM, Valente IM, Rodrigues JA. An overview on cardamonin. J Med Food. 2014 Jun;17(6):633-40.
| Cell experiment [1, 2]: | |
|
Cell lines |
Activated RAW 264.7 cells and whole blood, vascular smooth muscle cell |
|
Preparation method |
The solubility of this compound in DMSO is > 10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37 ℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
17–20 h |
|
Applications |
Cardamonin inhibited NO and PGE2 production from lipopolysaccharide- and IFNγ-induced RAW cells and whole blood with IC50 values of 11.4 μM and 26.8 μM, respectively. In whole blood, cardamonin inhibited the generation of TxB2. Cardamonin dose-dependently inhibited the generation of intracellular reactive oxygen species and secretion of TNF-α from RAW 264.7 cells with IC50 values of 12.8 μM and 4.6 μM, respectively. Treatment with Cardamonin (37, 74, or 111 μM) inhibited Ang II-induced proliferation of rat VSMCs. Cardamonin suppressed Ang II-stimulated migration of rat VSMCs. |
| Animal experiment [3, 4]: | |
|
Animal models |
Female ICR mice, Male Sprague-Dawley rats |
|
Dosage form |
Intraperitoneal injection, 0.02-20 mg/kg, daily for 4 consecutive days; oral administration, 3-30 mg/kg |
|
Application |
In female ICR mice, Cardamonin (0.02–2 mg/kg, i.p.) inhibited NO production. In male Sprague-Dawley rats, Cardamonin (3-30 mg/kg, oral administration) significantly inhibited PBQ-induced writhing. Cardamonin dose-dependently increased the withdrawal response latencies in carrageenan-induced hyperalgesia. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Ahmad S, Israf D A, Lajis N H, et al. Cardamonin, inhibits pro-inflammatory mediators in activated RAW 264.7 cells and whole blood[J]. European journal of pharmacology, 2006, 538(1): 188-194. [2]. Shen Y J, Zhu X X, Yang X, et al. Cardamonin inhibits angiotensin II-induced vascular smooth muscle cell proliferation and migration by downregulating p38 MAPK, Akt, and ERK phosphorylation[J]. Journal of natural medicines, 2014, 68(3): 623-629. [3]. Takahashi A, Yamamoto N, Murakami A. Cardamonin suppresses nitric oxide production via blocking the IFN-γ/STAT pathway in endotoxin-challenged peritoneal macrophages of ICR mice[J]. Life sciences, 2011, 89(9): 337-342. [4]. Park MK, et al. Novel anti-nociceptive effects of cardamonin via blocking expression of cyclooxygenase-2 andtransglutaminase-2. Pharmacol Biochem Behav. 2014 Mar;118:10-5. |
|
| Cas No. | 19309-14-9 | SDF | |
| 别名 | 小豆蔻明; (E)-Cardamomin; (E)-Alpinetin chalcone | ||
| 化学名 | (E)-1-(2,4-dihydroxy-6-methoxyphenyl)-3-phenylprop-2-en-1-one | ||
| Canonical SMILES | OC1=C(C(/C=C/C2=CC=CC=C2)=O)C(OC)=CC(O)=C1 | ||
| 分子式 | C16H14O4 | 分子量 | 270.28 |
| 溶解度 | DMF: 25 mg/ml,DMSO: 25 mg/ml,DMSO:PBS(pH 7.2) (1:4): 0.2 mg/ml,Ethanol: 1 mg/ml | 储存条件 | Store at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.6999 mL | 18.4993 mL | 36.9987 mL |
| 5 mM | 0.74 mL | 3.6999 mL | 7.3997 mL |
| 10 mM | 0.37 mL | 1.8499 mL | 3.6999 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet